Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Graft-Versus-Host Disease

A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation

Bone Marrow Transplantation volume 28, pages 187–196 (2001)Cite this article

Abstract

Intravenous immunoglobulin is approved for use in allogeneic bone marrow transplant recipients for prevention of graft-versus-host disease (GVHD) and infections, but the minimally effective dose has not been established. In this multicenter, randomized, double-blind trial, patients undergoing allogeneic marrow transplantation were randomized to receive 100 mg/kg, 250 mg/kg, or 500 mg/kg doses of intravenous immunoglobulin. Each dose was given weekly for 90 days and then monthly until 1 year after transplant. Six hundred and eighteen patients were evaluated. Acute GVHD (grades 2–4) occurred in 39% of the patients (80 of 206) in the 100 mg/kg group, 42% of the patients (88 of 208) in the 250 mg/kg group, and in 35% of the patients (72 of 204) in the 500 mg/kg group (P = 0.344). Among patients with unrelated marrow donors, a higher dose of intravenous immunoglobulin (500 mg/kg) was associated with less acute GVHD (P = 0.07). The incidences of chronic GVHD, infection and interstitial pneumonia were similar for all three doses of intravenous immunoglobulin. The dose of intravenous immunoglobulin also had no effect on the types of infection, relapse of hematological malignancy or survival. Except for more frequent chills (P = 0.007) and headaches (P = 0.015) in patients given the 500 mg/kg or 250 mg/kg dose of immunoglobulin, adverse events were similar for all three doses. These results suggest that 100 mg/kg, 250 mg/kg, and 500 mg/kg doses of intravenous immunoglobulin are associated with similar incidences of GVHD and infections in most allogeneic marrow transplants. These results should be considered when designing cost-effective strategies for the use of intravenous immunoglobulin in allogeneic marrow transplants receiving other current regimens for prophylaxis of GVHD and infection. Bone Marrow Transplantation (2001) 28, 187–196.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Winston DJ, Ho WG, Lin CH et al. Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation Ann Intern Med 1987 106: 12–18

    Article  CAS  PubMed  Google Scholar 

  2. Bowden RA, Sayers M, Flournoy N et al. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation New Engl J Med 1986 314: 1006–1010

    Article  CAS  PubMed  Google Scholar 

  3. Condie RM, O'Reilly RJ . Prevention of cytomegalovirus infection by prophylaxis with an intravenous, hyperimmune, native, unmodified cytomegalovirus globulin. Randomized trial in bone marrow transplant recipients Am J Med 1984 76: 134–141

    Article  CAS  PubMed  Google Scholar 

  4. Kubanek B, Ernst P, Ostendorf P et al. Preliminary data of a controlled trial of intravenous hyperimmune globulin in the prevention of cytomegalovirus infection in bone marrow transplant recipients Transplant Proc 1985 17: 468–469

    Google Scholar 

  5. Petersen FB, Bowden RA, Thornquist M et al. The effect of prophylactic intravenous immune globulin on the incidence of septicemia in marrow transplant recipients Bone Marrow Transplant 1987 2: 141–148

    CAS  PubMed  Google Scholar 

  6. Graham-Pole J, Camitta B, Casper J et al. Intravenous immunoglobulin may lessen all forms of infection in patients receiving allogeneic bone marrow transplantation for acute lymphoblastic leukemia: a Pediatric Oncology Group study Bone Marrow Transplant 1988 3: 559–566

    CAS  PubMed  Google Scholar 

  7. Sullivan KM, Kopecky KJ, Jocom J et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation New Engl J Med 1990 323: 705–712

    Article  CAS  PubMed  Google Scholar 

  8. Winston DJ, Ho WG, Bartoni K, Champlin RE . Intravenous immunoglobulin and CMV-seronegative blood products for prevention of CMV infection and disease in bone marrow transplant recipients Bone Marrow Transplant 1993 12: 283–288

    CAS  PubMed  Google Scholar 

  9. Consensus on IVIG Lancet 1990 336: 470–472

  10. Bass EB, Powe NR, Goodman SN et al. Efficacy of immune globulin in preventing complications of bone marrow transplantation: a meta-analysis Bone Marrow Transplant 1993 12: 273–282

    CAS  PubMed  Google Scholar 

  11. Package Insert. Gaminune N 5% (Immune Globulin Intravenous (Human), 5%, Solvent/Detergent Treated). Bayer Corporation, Pharmaceutical Division, Elkhart, Indiana, USA

  12. Thomas ED, Storb R, Clift RA et al. Bone-marrow transplantation New Engl J Med 1975 292: 832, 895–902

    Google Scholar 

  13. Sullivan KM, Shulman HM, Storb R et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression Blood 1981 57: 267–276

    CAS  PubMed  Google Scholar 

  14. Mantel N, Haenszel W . Statistical aspects of the analysis of data from retrospective studies of disease J Natl Cancer Inst 1959 22: 719–748

    CAS  PubMed  Google Scholar 

  15. Kaplan EL, Meier P . Nonparametric estimation from incomplete observation J Am Stat Assoc 1958 53: 457–481

    Article  Google Scholar 

  16. Cox PR . Regression models and life-tables JR Statist Soc 1972 34: 187–220

    Google Scholar 

  17. Munoz A, Rosner B . Power and sample size for a collection of 2 × 2 tables Biometrics 1984 40: 995–1004

    Article  Google Scholar 

  18. Feinstein LC, Seidel K, Jocum J et al. Reduced dose intravenous immunoglobulin does not decrease transplant-related complications in adults given related donor marrow allografts Biol Blood Marrow Transplant 1999 5: 369–378

    Article  CAS  PubMed  Google Scholar 

  19. Winston DJ . Use of quinolone antimicrobial agents in immunocompromised patients In: Hooper DC, Wolfson JS (eds) Quinolone Antimicrobial Agents 2nd edn American Society for Microbiology: Washington, DC 1993 pp 435–471

    Google Scholar 

  20. Goodman JL, Winston DJ, Greenfield RA et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation New Engl J Med 1992 326: 845–851

    Article  CAS  PubMed  Google Scholar 

  21. Slavin MA, Osborne B, Adams R et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation – a prospective, randomized, double-blind study J Infect Dis 1995 171: 1545–1552

    Article  CAS  PubMed  Google Scholar 

  22. Winston DJ, Ho WG, Bartoni K et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplants: results of a placebo-controlled, double-blind trial Ann Intern Med 1993 118: 179–184

    Article  CAS  PubMed  Google Scholar 

  23. Goodrich JM, Bowden RA, Fisher L et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant Ann Intern Med 1993 118: 173–178

    Article  CAS  PubMed  Google Scholar 

  24. Bross DS, Tutschka PJ, Farmer ER et al. Predictive factors for acute graft-versus-host disease in patients transplanted with HLA-identical bone marrow Blood 1984 63: 1265–1270

    CAS  PubMed  Google Scholar 

  25. Nash RA, Pepe MS, Storb R et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate Blood 1992 80: 1838–1845

    CAS  PubMed  Google Scholar 

  26. Nademanee A, Schmidt GM, Parker P et al. The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone Blood 1995 86: 1228–1234

    CAS  PubMed  Google Scholar 

  27. Lazarus HM, Vogelsang, GB, Rowe JM . Prevention and treatment of acute graft-versus-host disease: the old and the new. A report from The Eastern Cooperative Oncology Group (ECOG) Bone Marrow Transplant 1997 19: 577–600

    Article  CAS  PubMed  Google Scholar 

  28. Guglielmo BJ, Wong-Beringer A, Linker CA . Immune globulin therapy in allogeneic bone marrow transplant: a critical review Bone Marrow Transplant 1994 13: 499–510

    CAS  PubMed  Google Scholar 

  29. Sullivan KM, Agura E, Anasetti C et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation Semin Hematol 1991 28: 250–259

    CAS  PubMed  Google Scholar 

  30. Sullivan KM, Storek J, Kopecky KJ et al. A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery Biol Blood Marrow Transplant 1996 2: 44–53

    CAS  PubMed  Google Scholar 

  31. Abdel-Mageed A, Graham-Pole J, Del Rosario MLU et al. Comparison of two doses of intravenous immunoglobulin after allogeneic bone marrow transplants Bone Marrow Transplant 1999 23: 929–932

    Article  CAS  PubMed  Google Scholar 

  32. Cottler-Fox M, Lynch M, Pickle LW et al. Some but not all benefits of intravenous immunoglobulin therapy after marrow transplantation appear to correlate with IgG trough levels Bone Marrow Transplant 1991 8: 27–33

    CAS  PubMed  Google Scholar 

  33. Klaesson S, Ringden O, Ljungman P et al. Does high-dose intravenous immune globulin treatment after bone marrow transplantation increase mortality in veno-occlusive disease of the liver Transplantation 1996 60: 1225–1230

    Article  Google Scholar 

Download references

Acknowledgements

We thank Dr Frank Norton of Alpha Therapeutic Corporation for assistance in preparation of the manuscript. We are also grateful to the following study coordinators for their valuable assistance during the study: Kathy Bartoni, RN, UCLA Center for the Health Sciences, Los Angeles, CA; Sharon Manson, RN, MS, Rush-Presbyterian-St Luke's Medical Center, Chicago, Illinois. We thank Katharine Fry for typing the manuscript. This work was supported by research grants from Alpha Therapeutic Corporation, Los Angeles, California.

Author information

Authors and Affiliations

  1. UCLA Center for the Health Sciences, Los Angeles, CA, USA

    DJ Winston, GJ Schiller & MC Territo

  2. Brigham and Women's Hospital, Boston, MA, USA

    JH Antin

  3. Vanderbilt University Medical Center, Nashville, TN, USA

    SN Wolff

  4. Dana Farber Cancer Institute, Boston, MA, USA

    BE Bierer

  5. Memorial Sloan-Kettering Cancer Center, New York, NY, USA

    T Small

  6. Tufts-New England Medical Center, Boston, MA, USA

    KB Miller

  7. Cancer Research Center and Department of Pediatrics, University of California at San Francisco, San Francisco, CA, USA

    C Linker & MJ Cowan

  8. Rush-Presbyterian-St Luke's Medical Center, Chicago, IL, USA

    H Kaizer

  9. Case Western Reserve University Hospital, Cleveland, OH, USA

    HM Lazarus

  10. University of Utah Hospital, Salt Lake City, UT, USA

    FB Petersen

  11. St Joseph's Hospital, Orange, CA, USA

    WG Ho

  12. Emory University Cancer Center, Atlanta, GA, USA

    JR Wingard

  13. Alpha Therapeutic Corporation, Los Angeles, CA, USA

    J Jiao, MA Petrarca & SA Tonetta

Authors
  1. DJ Winston
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. JH Antin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. SN Wolff
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. BE Bierer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T Small
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. KB Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C Linker
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. H Kaizer
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. HM Lazarus
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. FB Petersen
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. MJ Cowan
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. WG Ho
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. JR Wingard
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. GJ Schiller
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. MC Territo
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. J Jiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. MA Petrarca
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. SA Tonetta
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Winston, D., Antin, J., Wolff, S. et al. A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation. Bone Marrow Transplant 28, 187–196 (2001). https://doi.org/10.1038/sj.bmt.1703109

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703109

Keywords

This article is cited by

Search

Advanced search

Quick links